Sterling Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Sterling Capital Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.29K	Sell	1,513 -947	-38%	-$3.98K	﹤0.01%	2490
2026 Q1	$10.2K	Sell	2,460 -1,659	-40%	-$6.73K	﹤0.01%	2363
2025 Q4	$26.6K	Buy	4,119 +119	+3%	+$742	﹤0.01%	2077
2025 Q3	$22.4K	Buy	4,000 +2,426	+154%	+$10.5K	﹤0.01%	2089
2025 Q2	$5.21K	Buy	1,574 +620	+65%	+$1.78K	﹤0.01%	2490
2025 Q1	$2.77K	Sell	954 -799	-46%	-$2.42K	﹤0.01%	2451
2024 Q4	$6.24K	Buy	1,753 +1,560	+808%	+$7.19K	﹤0.01%	2358
2024 Q3	$961	Buy	+193	New	+$751	﹤0.01%	2551

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Sterling Capital Management's AQST Position: Q2 2026 in Review

Sterling Capital Management reduced its Aquestive Therapeutics (AQST) stake by 38% in Q2 2026, selling an estimated $3.98K and leaving 1,513 shares worth $6.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Sterling Capital Management first reported a position in AQST in Q3 2024 and has held it in 8 quarters since. The position peaked at $26.6K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Sterling Capital Management held 1,513 shares of Aquestive Therapeutics worth $6.29K as of Q2 2026.
Sterling Capital Management sold 947 Aquestive Therapeutics shares in Q2 2026, an estimated $3.98K.
Aquestive Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2490 holding.
Sterling Capital Management first reported a position in Aquestive Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Aquestive Therapeutics position peaked at $26.6K in Q4 2025.
185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.